Indian Antithrombotic Drugs market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Antithrombotic drugs are used to prevent or treat thrombus formation. The growing number of chronic diseases that lead to thrombosis coupled with the increase in geriatric population is expected to drive the market growth. In addition, many of the drugs of antithrombotics are off-patented and presence of generics with a lower cost are fuelling the market growth over the forecast period. Furthermore, the presence of strong drug pipelines such as Tecarfarin, TB-402 and others and their expected commercialization is projected to boost the market growth over the coming years. Moreover, unavailability of alternatives for antithrombotic drugs coupled with the new product developments and launches are expected to bolster the market growth. However, stringent regulatory policies and high cost of novel drugs are expected to hamper the market growth.
Growing demand for NOACS, the surge in hip and knee replacement surgeries, healthcare policies and programs by government, growing aging population are the major driving factors for the market growth in Indian antithrombotic drugs in India. The important drivers increasing demand for NOACS and healthcare policies and programs by the government. The increasing adoption rates of NOACS are driving the market growth. NOACs target either thrombin or factor Xa to prevent and treat thrombosis. They show quick action and do not require continuous monitoring. The high prevalence of chronic diseases that increase the risk of developing thrombosis and huge financial investment in research and development activities. In addition, high diagnostic rate and improvement in treatment are some of the impacting factors that drives the market growth.